John G Ullman & Associates Inc. Has $3 Million Stock Position in Avantor, Inc. (NYSE:AVTR)

John G Ullman & Associates Inc. raised its stake in Avantor, Inc. (NYSE:AVTR - Free Report) by 97.9% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 142,500 shares of the company's stock after acquiring an additional 70,500 shares during the period. John G Ullman & Associates Inc.'s holdings in Avantor were worth $3,002,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. MassMutual Private Wealth & Trust FSB increased its stake in shares of Avantor by 99.5% in the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 1,253 shares of the company's stock valued at $26,000 after purchasing an additional 625 shares during the last quarter. Global Retirement Partners LLC increased its stake in shares of Avantor by 76.7% in the 4th quarter. Global Retirement Partners LLC now owns 2,459 shares of the company's stock valued at $52,000 after purchasing an additional 1,067 shares during the last quarter. Nisa Investment Advisors LLC increased its stake in shares of Avantor by 69.6% in the 3rd quarter. Nisa Investment Advisors LLC now owns 2,035 shares of the company's stock valued at $53,000 after purchasing an additional 835 shares during the last quarter. UMB Bank n.a. increased its stake in shares of Avantor by 56.3% in the 4th quarter. UMB Bank n.a. now owns 2,981 shares of the company's stock valued at $63,000 after purchasing an additional 1,074 shares during the last quarter. Finally, CKW Financial Group increased its stake in shares of Avantor by 116.7% in the 4th quarter. CKW Financial Group now owns 5,200 shares of the company's stock valued at $110,000 after purchasing an additional 2,800 shares during the last quarter. 95.08% of the stock is owned by institutional investors and hedge funds.

Remove Ads

Insider Activity

In other news, EVP James Bramwell sold 3,758 shares of the business's stock in a transaction dated Wednesday, February 26th. The stock was sold at an average price of $17.53, for a total value of $65,877.74. Following the transaction, the executive vice president now directly owns 87,379 shares of the company's stock, valued at $1,531,753.87. The trade was a 4.12 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CAO Steven W. Eck sold 4,907 shares of the company's stock in a transaction that occurred on Wednesday, February 26th. The stock was sold at an average price of $17.53, for a total value of $86,019.71. Following the transaction, the chief accounting officer now directly owns 40,604 shares in the company, valued at approximately $711,788.12. This trade represents a 10.78 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 1.30% of the stock is owned by company insiders.

Avantor Trading Up 1.6 %

AVTR traded up $0.25 during midday trading on Wednesday, hitting $15.75. 7,605,768 shares of the company were exchanged, compared to its average volume of 5,941,737. The firm has a market capitalization of $10.73 billion, a P/E ratio of 15.15, a P/E/G ratio of 1.55 and a beta of 1.30. Avantor, Inc. has a 1-year low of $15.37 and a 1-year high of $28.00. The firm's 50 day moving average price is $20.18 and its 200-day moving average price is $22.47. The company has a quick ratio of 0.70, a current ratio of 1.07 and a debt-to-equity ratio of 0.54.

Avantor (NYSE:AVTR - Get Free Report) last announced its earnings results on Wednesday, February 12th. The company reported $0.27 EPS for the quarter, topping the consensus estimate of $0.26 by $0.01. Avantor had a return on equity of 12.17% and a net margin of 10.49%. During the same quarter in the prior year, the firm posted $0.22 EPS. As a group, equities analysts forecast that Avantor, Inc. will post 1.06 EPS for the current fiscal year.

Analysts Set New Price Targets

Several equities analysts have recently issued reports on the company. Stifel Nicolaus decreased their price target on Avantor from $28.00 to $26.00 and set a "buy" rating on the stock in a research note on Monday, February 10th. Morgan Stanley decreased their price target on Avantor from $27.00 to $25.00 and set an "overweight" rating on the stock in a research note on Monday, February 10th. Royal Bank of Canada decreased their price target on Avantor from $33.00 to $31.00 and set an "outperform" rating on the stock in a research note on Monday, February 10th. Raymond James restated an "outperform" rating and set a $24.00 price objective (down previously from $26.00) on shares of Avantor in a research report on Monday, February 10th. Finally, Barclays reduced their price objective on Avantor from $26.00 to $23.00 and set an "overweight" rating on the stock in a research report on Monday, February 10th. Three analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus target price of $25.50.

Avantor Profile

Avantor, Inc engages in the provision of mission-critical products and services to customers in the biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, education and microbiology products, clinical trial kits, peristaltic pumps, and fluid handling tips.